Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Rhea-AI Summary
Microbot Medical (Nasdaq: MBOT) reported greater than 100% quarter-over-quarter growth in revenue and new customers for Q2 2026 following the Full Market Release of the LIBERTY Endovascular Robotic System on April 13, 2026.
The company expanded U.S. sales territories from 4 to 8, plans 12 by year-end, signed a distribution agreement with Lovell Government Services for federal healthcare systems, gained marketing clearance in Israel, and agreed to establish a second manufacturing site to support demand and potential margin expansion.
Positive
- Revenue and new customers grew by more than 100% QoQ in Q2 2026
- LIBERTY System Full Market Release began April 13, 2026
- Procedure volume increased at Limited Market Release health systems in Q2 2026
- U.S. sales territories doubled from 4 to 8 in Q2 2026, targeting 12 by year-end
- Agreement with Lovell Government Services to serve federal healthcare systems
- Israeli marketing clearance makes Israel first market outside U.S. for LIBERTY System
- Agreement for a second manufacturing site to support demand and potential margin expansion
Negative
- None.
News Market Reaction – MBOT
On the day this news was published, MBOT declined 1.55%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $129.63M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 30 | Manufacturing expansion deal | Positive | +4.3% | Sanmina engaged as additional LIBERTY manufacturer to expand capacity and efficiency. |
| Jun 25 | Industry award win | Positive | -1.1% | LIBERTY won Innovative Start-Up Award, highlighting system innovation and adoption. |
| Jun 23 | New PA health system | Positive | -1.6% | First Pennsylvania academic health system adopted LIBERTY, broadening regional footprint. |
| Jun 16 | Federal access agreement | Positive | +0.0% | Lovell agreement opened access to extensive U.S. federal healthcare facilities. |
| Jun 09 | First Michigan adopter | Positive | -2.5% | Large Michigan health system became first Midwest LIBERTY customer, supporting expansion. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive commercial and award headlines have often met with flat-to-negative next-day price reactions, with only one clear upside reaction out of five events.
Key Terms
endovascular medical
full market release financial
limited market release financial
marketing clearance regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
The Company is experiencing rising demand and increasing pipeline for the LIBERTY System since commencing the Full Market Release in April
Heightened awareness generating interest from leading health systems across the U.S. as Company plans to increase its U.S. sales territories from 8 to 12 and enter international markets by the end of 2026
HINGHAM, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, is reporting greater than
Furthermore, health systems that had adopted the LIBERTY System during the Limited Market Release (LMR) have increased their procedure volume in the second quarter ended June 30, 2026, due to site expansion and more users migrating to the system, compared to the first quarter ended March 31, 2026. With the rising interest from leading health systems, the Company broadened its sales footprint from 4 to 8 sales territories during the second quarter of 2026 and is on track to have 12 territories across the U.S. by the end of the year.
Moreover, the Company recently received marketing clearance for the LIBERTY System from the Israeli Ministry of Health's AMAR Division, making Israel the first country outside of the U.S. to approve the system. To ensure the Company has the capacity to meet current and future demand, it recently entered into an agreement to establish a second manufacturing site, positioning the Company for potential long-term margin expansion as volumes scale.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
